Previous 10 | Next 10 |
NEW YORK, June 09, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced the appointment of M. Michelle Berrey,...
Intercept Pharmaceuticals (ICPT) announces the appointment of Andrew Saik as the company's chief financial officer.Saik brings more than 20 years of biopharma finance experience to his new role at Intercept.He was previously chief financial officer of Vyne Therapeutics, where h...
NEW YORK, June 07, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced the appointment of Andrew Saik as Chie...
NEW YORK, May 27, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Jerry Durso, President and Chief E...
NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that the Ocaliva (obeticholic acid or O...
The shares of Intercept Pharmaceuticals ([[ICPT]] -1.7%) have come under pressure as FDA issues a statement restricting the use of the liver disease therapy Ocaliva (obeticholic acid).Citing the possibility of harmful effects, the regulator has restricted the use of the treatment for patients...
With a loss of more than a third in value so far, NGM Biopharmaceuticals ([[NGM]] -40.1%) is likely to post its biggest one-day loss after announcing its candidate for non-alcoholic steatohepatitis ((NASH)), aldafermin failed to meet the primary endpoint in a Phase 2/3 trial.Highlighting...
The following slide deck was published by Intercept Pharmaceuticals, Inc. in conjunction with this event. For further details see: Intercept Pharmaceuticals (ICPT) Investor Presentation - Slideshow
NEW YORK, May 12, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Jerry Durso, President and Chief E...
Image source: The Motley Fool. Intercept Pharmaceuticals Inc (NASDAQ: ICPT) Q1 2021 Earnings Call May 6, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: Intercept Pharmaceuticals Inc (ICPT) Q1 2021 Earnings Call Tra...
News, Short Squeeze, Breakout and More Instantly...
Intercept Pharmaceuticals Inc. Company Name:
ICPT Stock Symbol:
NASDAQ Market:
Intercept Pharmaceuticals Inc. Website:
MORRISTOWN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced five abs...
sNDA intended to satisfy post-marketing requirements to confirm a clinical benefit in patients with PBC Precedent-setting submission includes data from post-marketing studies COBALT and Study 401 as well as real-world evidence from a claims database and patient registries FDA has assign...
Data from two Phase 2 studies in PBC show combination of OCA + bezafibrate achieved biochemical remission (normalization of ALP, total bilirubin, GGT, ALT and AST) in 40-44% of patients in the first 12 weeks OCA 5 or 5-10 mg + bezafibrate 400 mg cohorts in both studies showed a >60% ...